Report Categories
View AllRecent Articles
View All
ESPR Esperion Therapeutics reports Q4 2025 EPS miss shares post small gains even as earnings lag analyst estimates
MATW Matthews delivers massive Q1 2026 earnings upside as EPS far outpaces analyst estimates shares edge higher
What Ares Capital ARCC does better than 90 of companies Selling Pressure 20260508
EBS Emergent BioSolutions crushes EPS estimates by 183 but faces revenue headwinds with 30 annual decline shares edge higher